Feuchtenberger M, Voll R E, Kneitz C
Medizinische Klinik und Poliklinik II (ZIM), Schwerpunkt Rheumatologie und Klinische Immunologie, Klinikum der Julius-Maximilians-Universität Würzburg.
Z Rheumatol. 2010 Nov;69(9):803-12. doi: 10.1007/s00393-010-0707-0.
Patients with autoimmune or rheumatic diseases are at increased risk for infectious complications due to immunosuppressive therapy and/or the underlying immunological disease itself. To date, the consistent use of vaccinations in this patient group has been limited due to concerns about flair-ups or lack of efficacy. In prospective studies neither an increased risk of disease flair-ups nor of initiation of autoimmune disorders was found as yet; however, the data is still considered insufficient (small studies including only patients in remission). Vaccination with non-live vaccines can generally be regarded as safe and relatively effective, even in patients on immunosuppressive therapy. Since the immune response to vaccination may be markedly impaired depending on the medication used and the underlying autoimmune disease, monitoring of both serum titers and of patients' vaccination schedules should form an integral part of rheumatological care.
自身免疫性疾病或风湿性疾病患者由于免疫抑制治疗和/或潜在的免疫性疾病本身,发生感染并发症的风险增加。迄今为止,由于担心病情复发或疫苗缺乏效力,该患者群体中疫苗接种的持续使用率一直有限。在前瞻性研究中,尚未发现疾病复发风险增加或自身免疫性疾病发作风险增加;然而,数据仍被认为不足(仅包括缓解期患者的小型研究)。即使对于接受免疫抑制治疗的患者,接种非活疫苗通常也可被视为安全且相对有效。由于根据所用药物和潜在的自身免疫性疾病,对疫苗接种的免疫反应可能会显著受损,监测血清滴度和患者的疫苗接种计划应成为风湿病护理的一个组成部分。